Participating countries and number of treated patients
United Kingdom (7 patients treated)
Susceptibility testing

Methods
Antifungal susceptibility testing for baseline isolates was conducted according to standard
Clinical and Laboratory Standards Institute (CLSI) methods and breakpoints (i.e. anidulafungin non-susceptibility >2 µg/mL; fluconazole resistance ≥64 µg/mL; voriconazole resistance ≥4 µg/mL) [1, 2] .
Results
A total of 167 baseline isolates underwent susceptibility testing, and most of these (n = 153) were fully susceptible to anidulafungin, fluconazole, and voriconazole. However, 2/96 Candida albicans isolates were not susceptible to both fluconazole and voriconazole, 4/27 C. glabrata were not susceptible to fluconazole, 5/21 C. parapsilosis were not susceptible to fluconazole and 1/21 were not susceptible to anidulafungin, and 2/2 C. krusei were not susceptible to fluconazole.
Overall minimum inhibitory concentrations required to inhibit the growth of 50% of organisms (MIC 50 ) and of 90% of organisms (MIC 90 ) for anidulafungin, fluconazole, and voriconazole were 0.03 and 0.5, 0.5 and 8, and 0.015 and 0.5 μg/mL, respectively. The anidulafungin MIC 90 for C. parapsilosis was 2 μg/mL higher than for other species (i.e. 0.03-0.12 μg/mL).
Prior systemic antifungals at baseline in the modified intent-to-treat (MITT) population
Prior systemic antifungal treatment, n (%) 69 (40.6) Fluconazole Caspofungin Voriconazole Amphotericin B 54 (31.8) 10 (5.9) 6 (3.5) 2 (1.2)
Sites of deep-tissue Candida infection at baseline in the MITT population
Site
No 
Time to negative blood culture
The time (in days) from start of study drug to first negative blood culture (until the end of anidulafungin treatment) was assessed in those patients who had Candida bloodstream infection only (not including those patients who also had a deep-tissue Candida infection).
Patients who received less than 3 days of anidulafungin were excluded. As a result of this narrow definition, only 98 patients were eligible for inclusion into this analysis. Moreover, any negative blood cultures on the first day of dosing were ignored in order to prevent the possibility of the first negative culture being recorded as occurring on the same day as initiation of study drug. By definition, it was thus assumed that a patient was still infected with Candida on the first day of dosing and that no patient had eradication on Day 1 of treatment. Out of this group, 87 patients had a first negative blood culture not followed by a positive blood culture in the next 3 days (or 4 days if this negative was observed on or after Day 10) whilst on anidulafungin treatment. Mean (SD) day of first negative blood culture in these 87 patients was 3.7 (3.07), range 2-17. A Kaplan-Meier curve (see Figure S1 ) shows that >50% of the 98 eligible patients achieved a first negative blood culture by Day 2.
Figure S1. Kaplan-Meier estimate of day of first negative blood culture in eligible modified intent-to-treat patients Day 1 represents the first day of anidulafungin therapy. 
Incidence of treatment-related adverse events in the overall safety population (n = 216)
